• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 19th January 2011

Economic Evidence and NHS Reforms in England

OHE collaborated with the Centre for Health Economics of the University of York in hosting workshop for policy makers and their advisers on NHS reforms. Discussion centred on economic evidence needed to drive the reforms and the gaps that now…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE collaborated with the Centre for Health Economics of the University of York in hosting workshop for policy makers and their advisers on NHS reforms. Discussion centred on economic evidence needed to drive the reforms and the gaps that now exist. The post reports key concerns and observations.

The NHS White Paper published in July 2010, ‘Equity and Excellence: Liberating the NHS', announced major reforms to health care in England.  In December, OHE and the Centre for Health Economics (CHE) of the University of York held an interactive workshop for policy makers, implementers and their advisers.  Its purpose was to identify the economic evidence needed for the reforms and the current gaps in evidence.  Sessions dealt with: the growing importance of measuring patient outcomes; the economics of commissioning based on consortia of general medical practitioners (GPs); the role of competition and private sector providers; and the productivity and efficiency of the NHS.  Key discussion points are outlined below.

A consistent theme of the reforms is measuring the outcomes for patients, often as reported by patients themselves, and acting on that information to improve both efficiency and results.  For example, early results of patient-reported outcomes from common non-emergency surgical procedures have raised fundamental questions about which patients are referred for surgery and how well they respond to treatment.  Making wider use of such outcomes measures may allow evidence-based resource allocation across a wide range of treatments and providers.  Much remains to be done, however, before the evidence is sufficient.

The reforms foresee substantially increasing the responsibility of local consortia of GP practices, giving them both the responsibility for deciding which health care services are available locally and managing the funds to pay for them.  This is different from the experiment with ‘fundholding’ by individual GP practices in the 1990s: the scale of responsibility is much greater and will include all GPs, not just those who volunteer.  Moreover, uncertainty about the volume and mix of demand for care means that GP consortia budgets are at risk of significant over- or under-spending, however well-managed.  The size of the consortia, as yet unclear, will be important: the smaller the population served by a consortium, the greater the need for an effective means for adjusting budgets to variations in actual demand.  Further research is required to understand the relationship between risk and consortia size.

The NHS internal market was created in 1991.  For the first few years, the emphasis was on both price and quality competition; more recently, the focus has shifted to fixed prices, with competition based of quality.  At the same time, the role for competition from private sector providers has been increased, although such providers still account for a very small portion of tax-funded health care in England.  The 2010 White Paper reinforces the intention to encourage and broaden competition among providers of NHS funded care, creating new forms of ‘social enterprise’ to run NHS services.  The impact on quality and efficiency will need to be evaluated.

Increasing health care productivity is a continuing challenge.  New, more sophisticated methods for measuring productivity suggest that the NHS is achieving broadly constant returns to scale over time.  Nevertheless, wide variations in productivity occur across NHS organisations.  Raising the performance of the least productive could save the NHS billions of pounds.

  • Healthcare Systems
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!